Kian Behbakht
Distinguished in Virilizing Ovarian Tumor

Dr. Kian Behbakht

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Denver Health And Hospital Authority
777 Bannock St, 
Denver, CO 
Accepting New Patients
Distinguished in Virilizing Ovarian Tumor
Denver Health And Hospital Authority
777 Bannock St, 
Denver, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kian Behbakht is a Gynecologic Oncologist and an Oncologist in Denver, Colorado. Dr. Behbakht is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Vulvectomy, and Hysterectomy. Dr. Behbakht is currently accepting new patients.

His clinical research consists of co-authoring 83 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in CO
Hospital Affiliations
University Of Colorado Hospital Authority
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

DENVER HEALTH AND HOSPITAL AUTHORITY
777 Bannock St, Denver, CO 80204
Other Locations
UNIVERSITY PHYSICIANS INCORPORATED
12605 E 16th Ave, Uchealth Anschutz Medical, Aurora, CO 80045
UNIVERSITY PHYSICIANS INCORPORATED
1635 Aurora Ct, Aurora, CO 80045
UNIVERSITY PHYSICIANS INCORPORATED
13123 E 16th Ave, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
View 5 Less Clinical Trials

80 Total Publications

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.
A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.
Journal: Gynecologic oncology
Published: May 12, 2025
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Saketh R. Guntupalli
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Saketh R. Guntupalli
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Denver Health And Hospital Authority

777 Bannock St, 
Denver, CO 
 (0.1 miles away)
303-436-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Saketh Guntupalli is a Gynecologic Oncologist and an Oncologist in Denver, Colorado. Dr. Guntupalli is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy. Dr. Guntupalli is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Jeffrey A. James
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Jeffrey A. James
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

Healthone Clinic Services-Surgical Specialties LLC

10107 Ridgegate Pkwy, Suite 120, 
Lone Tree, CO 
 (15.1 miles away)
303-955-7574
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey James is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Lone Tree, Colorado. Dr. James is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Virilizing Ovarian Tumor, Vaginectomy, and Oophorectomy.

Distinguished in Virilizing Ovarian Tumor
Dr. Dirk P. Pikaart
Gynecologic Oncology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Dirk P. Pikaart
Gynecologic Oncology | Oncology

Poudre Valley Medical Group LLC

525 Bob Peters Grv, Suite 309, 
Colorado Springs, CO 
 (62.1 miles away)
719-365-6464
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dirk Pikaart is a Gynecologic Oncologist and an Oncologist in Colorado Springs, Colorado. Dr. Pikaart is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Vulvar Cancer, Malignant Mixed Mullerian Tumor, Splenectomy, and Hysterectomy. Dr. Pikaart is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Behbakht's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile